Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cell Metabolism

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cmet.2007.12.006PMID 18177717
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.

  2008influential reference
• Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats

  2007cited by this paper
• Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?

  2007cited by this paper
• CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health

  2007cited by this paper
• Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

  2007cited by this paper
• Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

  2006cited by this paper
• Endocannabinoids in the regulation of appetite and body weight

  2005cited by this paper
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

  2005cited by this paper
• Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

  2003cited by this paper
• Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors

  1997cited by this paper

• Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development.

  2019cites this paper
• The Effects of a Neutral Cannabinoid-1 Receptor Antagonist on Intravenous Nicotine Self Administration Behaviour

  2014cites this paper
• The atypical cannabinoid O‐1602 stimulates food intake and adiposity in rats

  2012cites this paper
• REGULACIÓN DE LA EXPRESIÓN Y FUNCIÓN DEL RECEPTOR GPR55 EN LA HOMEOSTASIS ENERGÉTICA Y METABÓLICA

  2012cites this paper
• Drug Metabolism in Drug Safety Evaluation

  2012cites this paper
• Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant

  2010cites this paper
• Endocannabinoids in the aetiopathology of obesity – Central mechanisms

  2010cites this paper
• Regulation of lipid metabolism by energy availability: a role for the central nervous system

  2010cites this paper
• Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats.

  2009cites this paper
• Molecular mechanisms for the persistent bronchodilatory effect of the β2‐adrenoceptor agonist salmeterol

  2009cites this paper
• Management Through Risk Factor Modification

  2008cites this paper
• Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre‐clinical and clinical studies

  2008cites this paper
• The Discovery of Taranabant, a Selective Cannabinoid‐1 Receptor Inverse Agonist for the Treatment of Obesity

  2008cites this paper
• Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese Rats

  2008cites this paper
• Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.

  2008cites this paper